Ontology highlight
ABSTRACT:
(group 1) unchallenged;
(group 2) LPS-challenged;
(group 3) LPS-challenged following pre-treatment and sustained treatment with lower (5 - 7.5 x 105 Da) molecular weight HA (Bioniche Animal Health, Pullman, WA) at 10 mg/ml;
(group 4) LPS-challenged following pre-treatment and sustained treatment with higher (3 x 106 Da) molecular weight HA (Pfizer Animal Health, New York, NY) at 5 mg/ml.
Microarray data were analyzed using dChip version 1.3 (Harvard University, Cambridge, MA). Array normalization was performed using the invariant set procedure; model-based expression indices (MBEI) were computed using only perfect match probes. Probe-set level data identified as array outliers by dChip were omitted and considered missing data in subsequent analyses of the log (base 2) MBEI values were then exported to BRB ArrayTools version 3.2.3 for further analysis (National Cancer Institute, Bethesda, MD). Paired t-tests compared gene expression between the unchallenged control group (group 1) and the LPS-challenged control group (group 2).
A two-way ANOVA compared gene expression among the LPS-challenged control group (group 2) and the two HA-treated groups (groups 3 and 4), blocking on horse. For the probe sets showing differential expression among the three LPS-challenged groups (p<0.005), pairwise comparisons were performed and p-values were adjusted by Holm's method. All tests involving gene expression data used a random variance model.
ORGANISM(S): Equus caballus
DISEASE(S): normal
SUBMITTER: Kelly Santangelo
PROVIDER: E-MEXP-940 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Arthritis research & therapy 20070101 1
Numerous investigations have reported the efficacy of exogenous hyaluronan (HA) in modulating acute and chronic inflammation. The current study was performed to determine the in vitro effects of lower and higher molecular weight HA on lipopolysaccharide (LPS)-challenged fibroblast-like synovial cells. Normal synovial fibroblasts were cultured in triplicate to one of four groups: group 1, unchallenged; group 2, LPS-challenged (20 ng/ml); group 3, LPS-challenged following preteatment and sustained ...[more]